secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001193125-26-160355
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics prices $150M stock offering; provides Haduvio trial updates
------------------------------------------------------------------------------

- Offering of 11.6M shares at $13.00/sh; net proceeds ~$141.1M (or ~$162.4M if option exercised).
- Cash, cash equivalents and marketable securities ~$171.8M as of March 31, 2026.
- Cash runway extended through 2029, funding two Phase 3 IPF-cough trials and Phase 2b in non-IPF ILD and RCC.
- First Phase 3 IPF trial starts Q2 2026; topline results expected H1 2028; second Phase 3 in H2 2026 with results H2 2027.
- Phase 2b for RCC begins Q2 2026, topline results H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526160355/0001193125-26-160355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526160355/d587027d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-160355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer